GSK-J4 has nevertheless been proposed for application in several cancer types, particularly in vivo of acute myeloid leukemia, breast cancer, TAL1 positive T-ALL, colorectal cancer and osteosarcoma (Table 2) (74, 78, 93, 99, 106, 131–137). This evidence concerns the gene TAL1 and acute lymphoblastic leukemia.